Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of SV003 in Healthy Participants
NCT07469085Phase 1Recruiting
- Sponsor
- Shanghai Synvida Biotechnology Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SV003 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 3 months. Started Apr 2026; status: recruiting.
02
Drugs
SV003
Beyond the preview
Go deeper on NCT07469085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469085.